# Primary Biliary Cholangitis

Primary biliary cholangitis is usually diagnosed serologically in the setting of cholestatic liver tests. Management centers on prompt ursodeoxycholic acid, biochemical risk reassessment, escalation for inadequate response or intolerance, symptom-directed care, fibrosis assessment, and surveillance for complications.

**Clinical question:** How should physicians confirm, risk stratify, treat, and monitor adults with primary biliary cholangitis?

Updated: 2026-08-21T00:30:01.460998+00:00

## What matters in practice
- In most patients, a cholestatic liver-test pattern plus a PBC-specific autoantibody, typically antimitochondrial antibody, establishes PBC without liver biopsy. [13]
- Initiate ursodeoxycholic acid promptly and reassess biochemical response after at least 12 months; approximately 40% of patients do not meet response criteria. [18][19]
- Persistent biochemical activity, particularly incomplete alkaline phosphatase normalization, identifies residual risk and should prompt structured reassessment and consideration of approved second-line therapy. [18][23]
- Elafibranor is FDA-approved under accelerated approval with UDCA for inadequate responders or alone when UDCA is intolerable; survival benefit and prevention of decompensation have not been demonstrated. [2]
- Obeticholic acid is contraindicated in advanced cirrhosis, defined by current or prior decompensation or portal-hypertension features; discontinue permanently if cirrhosis progresses to advanced disease or clinically significant liver-related adverse reactions occur. [5][6]

## Confirm PBC and exclude biliary obstruction

Diagnosis is generally noninvasive, but discordant presentations require a broader cholestasis evaluation.

For chronic cholestatic liver tests, obtain PBC serology, particularly antimitochondrial antibody, and abdominal ultrasound to assess for biliary obstruction. The combination of cholestatic alkaline phosphatase and/or gamma-glutamyl transferase elevation with a PBC-specific autoantibody is sufficient for diagnosis in most patients and usually obviates biopsy. [13][17]

Do not infer disease severity from symptom burden. Pruritus and fatigue may substantially impair quality of life but do not correlate with disease stage. [9][10]

When autoimmune hepatitis overlap is suspected, liver biopsy with expert clinicopathologic review is recommended by the BSG/UK-PBC guideline because true overlap appears uncommon and histology guides management. [9]
- Obtain abdominal ultrasound during initial evaluation to evaluate obstruction rather than attributing all cholestasis to PBC. [17]
- Assess and document pruritus and fatigue at diagnosis and longitudinally, separately from biochemical risk. [9]
- Refer patients with advanced disease, clinically significant events, uncertain diagnosis, or suspected overlap for hepatology-level assessment. [10]

*Diagnostic decisions in suspected PBC. [9][13][17]*

| Clinical situation | Action | Interpretation or next step |
| --- | --- | --- |
| Cholestatic liver tests | Order antimitochondrial antibody and abdominal ultrasound. [13][17] | Cholestatic tests plus a PBC-specific autoantibody establish PBC in most patients. [13] |
| Imaging suggests obstruction | Evaluate the obstructive process rather than assuming isolated PBC. [17] | Biliary obstruction is an essential alternative explanation for cholestasis. [17] |
| Suspected autoimmune hepatitis overlap | Obtain liver biopsy with expert clinicopathologic review. [9] | Biopsy helps establish overlap and guide treatment. [9] |

## Use biochemical response and fibrosis assessment to identify residual risk

Risk assessment should be repeated rather than limited to the diagnostic visit.

PBC has heterogeneous progression: some patients progress slowly enough that disease may have limited clinical consequence, whereas others develop progressive biliary injury, fibrosis, cirrhosis, and end-stage liver disease. [13][10] Response to UDCA and longitudinal cholestatic biochemistry are central to risk stratification. [10][22]

ALP normalization is an important treatment objective. Patients with an insufficient UDCA response, including those whose results remain in an historically acceptable range but are not normalized, have higher risk of liver transplantation or death than those with normalized ALP. [18] A Global PBC Study Group analysis cited a bilirubin threshold of 0.6 times the upper limit of normal as necessary to detect risk discrimination. [23]

The BSG/UK-PBC guidance recommends annual serum liver tests and repeat documented risk assessment every 3 years. [21] In U.S. practice, monitoring frequency should also reflect treatment changes, biochemical activity, fibrosis stage, and decompensation risk.
- Track ALP and bilirubin longitudinally rather than treating a single value as definitive risk classification. [18][23]
- Reassess risk after an adequate UDCA trial and periodically thereafter; annual liver tests and a documented risk reassessment every 3 years are supported by BSG/UK-PBC guidance. [21]
- Evaluate for cirrhosis and portal-hypertension features before selecting obeticholic acid. [5][6]

*Risk-stratification findings that change management. [5][18][21][23]*

| Finding | Clinical implication | Management consequence |
| --- | --- | --- |
| ALP not normalized on therapy | Residual transplant or mortality risk remains higher than with normalized ALP. [18] | Confirm adherence, reassess disease activity and fibrosis, and consider approved escalation when UDCA response is inadequate. [2][18] |
| Bilirubin approaching or above 0.6 times ULN | May identify increased risk in Global PBC Study Group analyses. [23] | Prompt closer clinical assessment and risk reassessment. [21][23] |
| Current or prior decompensation or portal hypertension | Meets FDA definition of advanced cirrhosis for obeticholic acid restriction. [5] | Do not use obeticholic acid. [5][6] |

## Start UDCA, then escalate inadequate biochemical response or intolerance

Disease-modifying therapy and symptom control are related but distinct treatment tracks.

UDCA is first-line therapy and slows disease progression. [13] Contemporary treatment pathways use UDCA for a minimum of 12 months before formal biochemical response assessment. [19] The supplied evidence does not provide a source-supported U.S. dose; use current prescribing information and hepatology guidance when prescribing.

For adults with inadequate response to UDCA, elafibranor is FDA-approved in combination with UDCA; it is also approved as monotherapy when UDCA cannot be tolerated. Its 2024 approval is accelerated and based on ALP reduction; improvement in survival or prevention of liver decompensation has not been demonstrated. [2]

Obeticholic acid improved ALP in the pivotal placebo-controlled trial and received accelerated approval based on biochemical improvement. [4][12] However, FDA safety actions substantially constrain selection: it is contraindicated in advanced cirrhosis, including cirrhosis with current or prior decompensation or portal-hypertension features such as ascites, gastroesophageal varices, or persistent thrombocytopenia. [5] FDA also reports serious liver injury in treated patients without cirrhosis, reinforcing the need for clinical and laboratory monitoring. [4]
- Begin UDCA after diagnosis unless contraindicated or not tolerated; assess biochemical response after at least 12 months. [13][19]
- For inadequate UDCA response or UDCA intolerance, elafibranor is an FDA-approved option; counsel that its approval is based on ALP reduction and that clinical-outcome benefit remains unproven. [2]
- Before obeticholic acid, determine whether advanced cirrhosis is present; it is contraindicated if there is current or prior decompensation or portal hypertension. [5][6]
- During obeticholic acid therapy, monitor for disease progression and liver-related adverse reactions; permanently discontinue for progression to advanced cirrhosis or clinically significant liver-related adverse reactions. [6]

### Second-line selection and safety

Elafibranor and obeticholic acid have different regulatory and safety considerations. Elafibranor is approved under accelerated approval for inadequate UDCA response or UDCA intolerance, whereas obeticholic acid requires particular caution because of serious liver injury and its contraindication in advanced cirrhosis. [2][5][6]
- Do not equate ALP reduction with demonstrated survival or decompensation prevention for elafibranor; the FDA label explicitly states these outcomes have not been demonstrated. [2]
- Obeticholic acid exposure rises several-fold in moderate and severe hepatic impairment in the FDA review, supporting dose adjustment and close monitoring in hepatic impairment; use current labeling for exact dosing. [1]

*Disease-modifying therapies supported by supplied sources. [1][2][4][5][6][12][13][19]*

| Therapy | Role | Evidence and regulatory status | Key safety or monitoring issue |
| --- | --- | --- | --- |
| Ursodeoxycholic acid | First-line disease-modifying therapy. [13] | Slows progression; treatment pathways assess response after at least 12 months. [13][19] | Follow cholestatic tests and biochemical response longitudinally. [18][21] |
| Elafibranor | With UDCA for inadequate UDCA response; monotherapy if UDCA is not tolerated. [2] | FDA accelerated approval in 2024 based on ALP reduction. [2] | Survival benefit and prevention of decompensation have not been demonstrated. [2] |
| Obeticholic acid | Biochemical second-line option in appropriately selected patients. [4][12] | Accelerated approval was supported by ALP improvement. [4] | Contraindicated in advanced cirrhosis; monitor for progression and liver-related adverse reactions. [5][6] |

## Treat symptoms independently of biochemical disease control

Symptom burden requires active management even when fibrosis risk appears low.

Pruritus, fatigue, sicca symptoms, abdominal discomfort, and arthralgias or bone pain are part of the PBC morbidity burden. [10] Disease-modifying therapies and symptom-directed therapies should not be assumed to have the same effects: available review evidence notes that treatments modifying progression often do not improve symptoms, and symptom therapies do not substitute for biochemical disease control. [13]

Linerixibat received FDA orphan-product listing approval for cholestatic pruritus associated with PBC in adults, with an approval date of March 17, 2026 in the supplied FDA listing. [3] Because the supplied source does not include prescribing information, dosing, contraindications, drug interactions, and monitoring parameters cannot be specified here; verify the current FDA label before use.
- At each follow-up, ask specifically about itch and fatigue; their severity does not stage PBC. [9][10]
- Address quality-of-life symptoms alongside biochemical monitoring rather than waiting for advanced fibrosis. [13]
- For linerixibat, verify current U.S. labeling before prescribing because the supplied source supports indication and approval status but not use details. [3]

*Symptom-focused care principles in PBC. [3][9][10][13]*

| Issue | Clinical interpretation | Action |
| --- | --- | --- |
| Pruritus | Can be clinically important regardless of disease stage. [9][10] | Assess routinely and use symptom-directed therapy; linerixibat is FDA-listed for adult cholestatic pruritus associated with PBC. [3] |
| Fatigue | May markedly reduce quality of life but does not correlate with PBC stage. [9][10] | Document burden and evaluate/manage contributors separately from biochemical risk. [9][13] |
| Biochemical improvement without symptom relief | Disease-modifying and symptom-directed treatment effects may diverge. [13] | Continue risk-based therapy while adding symptom-focused management. [13] |

## Build follow-up around treatment response, fibrosis risk, and drug safety

Longitudinal care should detect biochemical nonresponse, clinical progression, and therapy-specific harm.

Use serial liver tests to establish trajectory after initiating or changing therapy. BSG/UK-PBC guidance recommends annual serum liver tests and documented repeat risk assessment every 3 years; more frequent evaluation is reasonable when biochemical activity persists, treatment is adjusted, or cirrhosis is present. [21]

For patients receiving obeticholic acid, FDA directs clinicians to monitor routinely for PBC progression using laboratory and clinical assessments and to assess for acute-on-chronic liver disease manifestations, including nausea, vomiting, diarrhea, jaundice, scleral icterus, or dark urine. Permanently discontinue for progression to advanced cirrhosis or development of these clinically significant liver-related adverse reactions. [6]
- Review ALP and bilirubin trends after the initial UDCA assessment period and after any treatment escalation. [18][19][23]
- Reevaluate for portal-hypertension or decompensation features before and during obeticholic acid exposure. [5][6]
- Use clinical symptoms to identify quality-of-life needs, not as a surrogate for fibrosis stage. [9][10]

*Practical follow-up framework supported by available sources. [5][6][19][21]*

| Time point | Assess | Action triggered |
| --- | --- | --- |
| After at least 12 months of UDCA | Biochemical response. [19] | If response is inadequate, reassess risk and consider an approved second-line option. [2][18] |
| At least annually | Serum liver tests. [21] | Use trends to identify persistent disease activity or progression. [18][21] |
| Every 3 years | Documented repeat risk assessment. [21] | Update prognosis and follow-up intensity. [21] |
| During obeticholic acid therapy | Clinical and laboratory evidence of progression or liver-related adverse reactions. [6] | Permanently discontinue for advanced-cirrhosis progression or clinically significant liver-related adverse reactions. [6] |

## Common questions

### Is liver biopsy required to diagnose primary biliary cholangitis?

Usually not. Cholestatic liver tests plus a PBC-specific autoantibody, typically antimitochondrial antibody, are sufficient in most patients. Biopsy is most useful when autoimmune hepatitis overlap is suspected or the presentation remains diagnostically discordant. [9][13]

### When should response to UDCA be assessed?

Current step-up treatment pathways assess biochemical response after a minimum of 12 months of UDCA. Persistent biochemical activity or failure to normalize ALP should prompt repeat risk assessment and consideration of escalation when appropriate. [18][19]

### Can obeticholic acid be used in cirrhosis?

It must not be used in advanced cirrhosis. FDA defines advanced cirrhosis as cirrhosis with current or prior decompensation or portal-hypertension features, including ascites, gastroesophageal varices, or persistent thrombocytopenia. [5][6]

### Does biochemical improvement reliably improve pruritus or fatigue?

No. Disease-modifying therapies may not materially improve symptoms, while symptom-directed therapies do not replace biochemical risk reduction. Assess and manage pruritus and fatigue independently. [9][13]

## References
1. 207999Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207999Orig1s000CrossR.pdf
2. highlights of prescribing information — www.fda.gov — https://www.fda.gov/media/180873/download
3. Search Orphan Drug Designations and Approvals — www.accessdata.fda.gov — https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=701919
4. Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis | FDA — www.fda.gov — https://www.fda.gov/drugs/drug-safety-communications/serious-liver-injury-being-observed-patients-without-cirrhosis-taking-ocaliva-obeticholic-acid-treat
5. Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis | FDA — www.fda.gov — https://www.fda.gov/drugs/drug-safety-and-availability/due-risk-serious-liver-injury-fda-restricts-use-ocaliva-obeticholic-acid-primary-biliary-cholangitis
6. Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis | FDA — www.fda.gov — https://www.fda.gov/drugs/fda-drug-safety-podcasts/due-risk-serious-liver-injury-fda-restricts-use-obeticholic-acid-ocaliva-primary-biliary-cholangitis
7. This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050708s050%2C050709s042%2C210115s002lbl.pdf
8. prescribing information - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020702Orig1s079correctedlbl.pdf
9. PBC primary biliary cholangitis treatment and management ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2018/03/28/gutjnl-2017-315259.full.pdf
10. The British Society of Gastroenterology/UK-PBC primary ... — gut.bmj.com — https://gut.bmj.com/content/67/9/1568
11. British Society of Gastroenterology and UK-PSC guidelines ... — gut.bmj.com — https://gut.bmj.com/content/68/8/1356
12. A Placebo-Controlled Trial of Obeticholic Acid in Primary ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1509840
13. Primary biliary cholangitis - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/344
14. Primary sclerosing cholangitis - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/847
15. P187 Are we identifying and treating PBC appropriately? 5 ... — gut.bmj.com — https://gut.bmj.com/content/70/Suppl_1/A140
16. A change of paradigm in PBC: Pursuing normal alkaline ... — www.thelancet.com — https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00331-0/fulltext
17. Primary biliary cholangitis — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01303-5/fulltext
18. Challenges facing the PBC community: insights from the PBC International Summit | Frontline Gastroenterology — fg.bmj.com — https://fg.bmj.com/content/early/2025/11/26/flgastro-2025-103262
19. Optimising Primary thErapy in pRimAry biliary cholangitis ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/16/3/e113812
20. Acute cholangitis - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/345
21. British Society of Gastroenterology/UK-PBC Primary Biliary ... — fg.bmj.com — https://fg.bmj.com/content/10/3/316
22. development and validation of the UDCA Response Score — www.thelancet.com — https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30163-8/fulltext
23. The relationship between disease activity and UDCA ... — www.thelancet.com — https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00249-3/fulltext
24. Assessment of adherence to guidelines for biochemical ... — bmjopengastro.bmj.com — https://bmjopengastro.bmj.com/content/12/1/e001899

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.